Johannes Scheid

USPTO Granted Patents = 13 (Patent Applications = 3)

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 3.9

ph-index = 4

Forward Citations = 41(Granted Patents)

Company Filing History:

13 out of 712

The Rockefeller University

patents

12 out of 4,547

California Institute of Technology

patents

where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12428472 - Human immunodeficiency virus neutralizing antibodies and methods of use thereof (2025-09-30),

2. 12071470 - Human immunodeficiency virus neutralizing antibodies and methods of use thereof (2024-08-27),

3. 12054538 - Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120 (2024-08-06),

4. 11634478 - Human immunodeficiency virus neutralizing antibodies and methods of use thereof (2023-04-25),

5. 11472868 - Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120 (2022-10-18),

6. 11155605 - Nucleic acids encoding broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 ENV subunits (2021-10-26),

7. 10889633 - Human immunodeficiency virus neutralizing antibodies and methods of use thereof (2021-01-12),

8. 10590187 - Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with gp120 (2020-03-17),

9. 10421803 - Broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 Env subunits (2019-09-24),

10. 9890207 - Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120 (2018-02-13),

11. 9783594 - Human immunodeficiency virus neutralizing antibodies and methods of use thereof (2017-10-10),

12. 9493549 - Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth (2016-11-15),

13. 8673307 - HIV-1 anti-core neutralizing antibodies that target a conformational epitope within the ALPHA5-helix of GP120 (2014-03-18),

Title: Innovations of Johannes Scheid

Introduction

Johannes Scheid is a prominent inventor based in New York, NY (US), known for his significant contributions to the field of immunology. He holds a total of 13 patents, showcasing his innovative approach to combating viral infections, particularly Human Immunodeficiency Virus (HIV).

Latest Patents

One of his latest patents includes the development of broadly neutralizing antibodies directed to epitopes of HIV. This invention provides compositions containing HIV antibodies that are used for prophylaxis, as well as methods for the diagnosis and treatment of HIV infection. His work in this area is crucial for advancing therapeutic strategies against HIV.

Career Highlights

Throughout his career, Johannes Scheid has worked with esteemed institutions such as The Rockefeller University and the California Institute of Technology. His research has significantly impacted the understanding and treatment of viral infections.

Collaborations

Some of his notable coworkers include Michel Nussenzweig and Pamela J Bjorkman, who have collaborated with him on various research projects.

Conclusion

Johannes Scheid's innovative work in the field of immunology, particularly regarding HIV, highlights his role as a leading inventor. His contributions continue to influence the development of effective treatments and preventive measures against viral infections.

This text is generated by artificial intelligence and may not be accurate.